Immatics Biotechnologies GmbH is a leading biopharmaceutical company specializing in the development of innovative cancer immunotherapies. Founded in 2000 as a spin-off from the Institute for Immunology at the University of Tübingen, Immatics has become a significant player in cancer research.
Immatics focuses on the development of peptide-based active immunotherapies based on the unique XPRESIDENT-Technologie. This platform enables the identification of Tumor-associated peptides (TUMAPs) and the development of targeted therapies. The main candidates include IMA101, IMA201, IMA202, IMA203 and IMA301, which are based on three ACT approaches (ACTolog, ACTengine and ACTallo).
The mission of Immatics is to unlock the full potential of T cells in the fight against cancer. The company places great emphasis on innovation and partnerships with leading pharmaceutical companies such as Bristol Myers Squibb, Genmab and GSK.
Although specific sustainability goals are not explicitly mentioned, Immatics focuses on developing therapies that improve the lives of cancer patients. By leveraging the XPRESIDENT-Technologie and developing targeted immunotherapies, the company contributes to improving healthcare.
Immatics recently presented preclinical proof-of-concept data for the lead candidate IMA402 and has begun to advance manufacturing. The company is listed on the Nasdaq under the ticker symbol IMTX and has close partnerships with renowned research institutions such as the MD Anderson Cancer Center.
Immatics is a pioneer in cancer research and is committed to developing effective therapies that can improve the lives of patients worldwide.
